SEC Form 4 · accession 0001246360-15-001885
SYNAGEVA BIOPHARMA CORP · GEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony Quinn
Officer — EVP, CMO & Head of R&D
Period of report
Apr 27, 2015
Accepted (ET)
Apr 29, 2015 · 5:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000911326
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 27, 2015 | M | 10,000 | $1.70 | A | 15,637 | D | |
| Common Stock | Apr 27, 2015 | S | 10,000 | $110.00 | D | 5,637 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.70 | Apr 27, 2015 | M | 10,000 | D | — | May 25, 2021 | Common Stock | 10,000 | 37,228 | D |
Explanation of responses
- F1The sale of shares of the Company's common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 6, 2015.
- F2The Stock Option granted the reporting person an option to purchase 47,228 shares of Common Stock (the "Shares"). 25% of the Shares vested and became exercisable on 05/25/2012, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter.